SARAH KO: Open Payments
NPI 1336699933 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$16,120 in 106 payments from 13 companies in 2025. Trend: 2023 $2,148 · 2024 $13,719 · 2025 $16,120
Speaker / faculty: $13,334Food & beverage: $2,536Education: $211Travel & lodging: $39
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 51 | $14,636 |
| Janssen Pharmaceuticals, Inc | 12 | $367 |
| Alkermes, Inc. | 10 | $226 |
| Neurocrine BioSciences, Inc. | 7 | $217 |
| E.R. Squibb & Sons, L.L.C. | 6 | $177 |
| Otsuka America Pharmaceutical, Inc. | 7 | $163 |
| ABBVIE INC. | 5 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Stryker Corporation | 1 | $31 |
Products named: UZEDY, AUSTEDO XR, ARISTADA, INGREZZA, SPRAVATO, INVEGA SUSTENNA, COBENFY, VRAYLAR.
Industry payments across CA — which companies pay providers there.
